Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical ... commercialise the candidate named HS-10535. Hansoh is also in line for ...
HS-10535, from Chinese biotech Hansoh Pharma. For the exclusive deal, Merck will make an upfront payment of $112 million to Hansoh Pharma, with the latter also being entitled to receive up to $1.9 ...
MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.
Also, Viking was seen by some as a potential acquisition target for Merck. However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and ...
The company has penned a deal to develop a potential GLP-1 weight loss therapy, HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the ...
However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and potentially formidable) competitor for Viking and greatly reduced the ...